



## **Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents**

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 3/17/2013

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <http://aidsinfo.nih.gov/e-news>.

**Table 16c. Interactions between Integrase Inhibitors or Maraviroc and Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors\* (Last updated February 12, 2013; last reviewed February 12, 2013) (page 1 of 2)**

\* Delavirdine (DLV), indinavir (IDV), and nelfinavir (NFV) are not included in this table. Refer to the DLV, IDV, and NFV Food and Drug Administration package inserts for information regarding drug interactions.

		<b>EVG/COBI/TDF/FTC</b>	<b>RAL</b>	<b>MVC</b>
<b>ATV +/- RTV</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI, ATV possible	With unboosted ATV RAL: AUC ↑ 72%  With (ATV 300 mg + RTV 100 mg) once daily RAL: AUC ↑ 41%	With unboosted ATV MVC: AUC ↑ 257%  With (ATV 300 mg + RTV 100 mg) once daily MVC: AUC ↑ 388%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 150 mg BID with ATV +/- RTV
<b>DRV</b> (always use with RTV)	<b>PK Data</b>	↑ or ↓ EVG, COBI, DRV possible	With (DRV 600 mg + RTV 100 mg) BID RAL: AUC ↓ 29% and C <sub>min</sub> ↑ 38%	With (DRV 600 mg + RTV 100 mg) BID MVC: AUC ↑ 305%  With (DRV 600 mg + RTV 100 mg) BID + ETR MVC: AUC ↑ 210%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 150 mg BID
<b>EFV</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI, EFV possible	EFV: AUC ↓ 36%	MVC: AUC ↓ 45%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 600 mg BID
<b>EVG/COBI/TDF/FTC</b>	<b>PK Data</b>	•	No data	↑ MVC possible
	<b>Dose</b>		<b>Do not co-administer.</b>	<b>Do not co-administer.</b>
<b>ETR</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI, ETR possible	ETR: C <sub>min</sub> ↓ 17%  RAL: C <sub>min</sub> ↓ 34%	MVC: AUC ↓ 53%, C <sub>max</sub> ↓ 60%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 600 mg BID in the absence of a potent CYP3A inhibitor
<b>FPV</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI, FPV possible	No significant effect	Unknown; ↑ MVC possible
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 150 mg BID
<b>LPV/r</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI, LPV possible  RTV and COBI have similar effects on CYP3A.	↓ RAL  ↔ LPV/r	MVC: AUC ↑ 295%  With LPV/r + EFV MVC: AUC ↑ 153%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 150 mg BID
<b>NVP</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI, NVP possible	No data	MVC: AUC ↔ and C <sub>max</sub> ↑ 54%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	Without PI MVC 300 mg BID  With PI (except TPV/r) MVC 150 mg BID

**Table 16c. Interactions between Integrase Inhibitors or Maraviroc and Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors\* (Last updated February 12, 2013; last reviewed February 12, 2013) (page 2 of 2)**

		<b>EVG/COBI/TDF/FTC</b>	<b>RAL</b>	<b>MVC</b>
<b>RAL</b>	<b>PK Data</b>	No data	•	RAL: AUC ↓ 37% MVC: AUC ↓ 21%
	<b>Dose</b>	<b>Do not co-administer.</b>		Standard
<b>RPV</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI, RPV possible	No data	No data
	<b>Dose</b>	<b>Do not co-administer.</b>	No data	No data
<b>RTV</b>	<b>PK Data</b>	↑ or ↓ EVG, COBI possible RTV and COBI have similar effects on CYP3A.	With RTV 100 mg BID RAL: AUC ↓ 16%	With RTV 100 mg BID MVC: AUC ↑ 161%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 150 mg BID
<b>SQV</b> (always use with RTV)	<b>PK Data</b>	↑ or ↓ EVG, COBI, SQV possible RTV and COBI have similar effects on CYP3A.	No data	With (SQV 1000 mg + RTV 100 mg) BID MVC: AUC ↑ 877%  With (SQV 1000 mg + RTV 100 mg) BID + EFV MVC: AUC ↑ 400%
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 150 mg BID
<b>TPV</b> (always use with RTV)	<b>PK Data</b>	↑ or ↓ EVG, COBI, TPV possible RTV and COBI have similar effects on CYP3A.	With (TPV 500 mg + RTV 200 mg) BID RAL: AUC ↓ 24%	With (TPV 500 mg + RTV 200 mg) BID MVC: No significant change in AUC  TPV: No data
	<b>Dose</b>	<b>Do not co-administer.</b>	Standard	MVC 300 mg BID

**Key to Abbreviations:** APV = amprenavir, ART = antiretroviral therapy, ATV = atazanavir, AUC = area under the curve, BID = twice daily, **COBI = cobicistat**, C<sub>max</sub> = maximum plasma concentration, C<sub>min</sub> = minimum plasma concentration, CYP = cytochrome P, DLV = delavirdine, DRV = darunavir, DRV/r = darunavir/ritonavir, EFV = efavirenz, **EVG = elvitegravir**, ETR = etravirine, FDA = Food and Drug Administration, FPV = fosamprenavir, IDV = indinavir, LPV = lopinavir, LPV/r = lopinavir/ritonavir, MVC = maraviroc, NFV = nelfinavir, NVP = nevirapine, PI = protease inhibitor, PK = pharmacokinetic, RAL = raltegravir, RPV = rilpivirine, RTV = ritonavir, SQV = saquinavir, SQV/r = saquinavir/ritonavir, TID = three times a day, TPV = tipranavir